MedTrace Logo

Clinical Trial to Compare the Pharmacokinetics of DP-R208

NCT02707224 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-03-23

No results posted yet for this study

Summary

A randomized, single-dose, open, crossover clinical trial to compare the pharmacokinetics of DP-R208 (Candesartan cilexetil and Rosuvastatin calcium fixed dose combinations) in comparison to each component administered alone in healthy male volunteers

Conditions

  • Healthy

Interventions

DRUG

DP-R208

Investigational product is prescribed to all of randomized subjects

DRUG

Candesartan cilexetil

Investigational product is prescribed to all of randomized subjects

DRUG

Rosuvastatin

Investigational product is prescribed to all of randomized subjects

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Principal Investigators

  • Min-Gul Kim, Ph.D · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-06-30
Completion
2015-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02707224 on ClinicalTrials.gov